<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN"
"http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>Untitled Document</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<style type="text/css">
body {
background:#fff;
margin:10px;
}
table {
margin-bottom:10px;
}
.yello {
background:#ffc;
padding:10px;
border:1px #c93 solid;
text-align:center;
}
.yello h1 {
color:#c60;
font-family:Arial, Helvetica, sans-serif;
font-weight:bold;
font-size:18px;
margin:0 25px;
}
.yello h2 {
text-transform:uppercase;
font-size:12px;
font-family:Verdana, Arial, Helvetica, sans-serif;
margin:0 0 5px 0;
}
#sec {
background:#7AA3BC;
padding:10px;
margin-right:10px;
border:1px #036 solid;
}
#wire {
background:#B3CEE0;
padding:10px;
margin-left:10px;
border:1px #036 solid;
}
#wire h1, #sec h1 {
font-family:Arial, Helvetica, sans-serif;
font-size:16px;
margin:0;
}
#wire a, #sec a {
color:#000;
}
img {
float:left;
margin:0;
}
p {
font-family:Verdana, Arial, Helvetica, sans-serif;
font-size:11px;
margin:5px 0 10px 0;
}
</style>
</head>
<body>
<table width="640" border="0" cellspacing="0" cellpadding="0">
<tr>
<td width="200" class="yello">
<h2>Limited Time Offer</h2>
<h1>Buy together for only $395!</h1>
<p>You'll receive<br>
<em>The Twenty Biotech <br>
Venture-backed Firms<br>
Most Likely to Succeed</em></p>
<p><strong>-
AND -</strong></p>
<p><em>Q3 '03 Biotech Investments, Mergers and Acquisitions</em><br>
for only $395</p><p><a href="https://secure.risingtidestudios.com/getPDF/?c=NKCQKDNU&PromotionalCode=spiced"><strong>Order Now! </strong></a></p>
</td>
<td valign="top">
<div id="wire">
<img src="http://venturereporter.net/media/20bio-binder.gif" width="171" height="163">
<h1>The Twenty Venture-backed Biotech Firms Most Likely to Succeed</h1>
<p>Venture Reporter's Twenty Venture-Backed Biotech Firms Most Likely To Succeed report includes profiles and
interviews with 20 of today's most promising venture-backed companies currently operating in the biotech sector.
Inside you will find graphs culled from Venture Reporter's exclusive numbers on biotech venture capital
investing, an in-depth analysis on the biotech space in 2003 and the companies vying to become the next
great biotech company, the twenty profiles of the selected firms and the results of a 20 question survey
on the state of the industry</p>
<p><a href="https://secure.risingtidestudios.com/getPDF/?c=B81F82BI&PromotionalCode=spiced">Available for $295</a></p>
<p><a href="https://secure.risingtidestudios.com/getPDF/?c=NKCQKDNU&PromotionalCode=spiced"><strong>OR Together with Q3 '03 Biotech Investments, Mergers and Acquisitions for only $395! </strong></a></p>
</div></td>
</tr>
</table>
<table width="640" border="0" cellspacing="0" cellpadding="0">
<tr>
<td valign="top">
<div id="sec">
<img src="http://venturereporter.net/media/Q3bio-binder.gif" width="171" height="163">
<h1>Q3 '03 Biotech Investments, Mergers and Acquisitions </h1>
<p>Venture Reporter's Q3 2003 Report with a Focus on Biotech and the War on Cancer includes 15 profiles of C-level executives
at biotech firms that either raised venture capital or made a merger or acquisition during the quarter, as well as an in-depth
analysis of the industry with supporting graphs. It has been over thirty years since Richard Nixon declared the War on Cancer,
and new techniques from the biotech world like vaccines, protein folding and G protein-coupled receptors are providing new
hope that significant victories may be close at hand</p>
<p><a href="https://secure.risingtidestudios.com/getPDF/?c=WTLZTMW3&PromotionalCode=spiced">Available for $295</a></p>
<p><strong><a href="https://secure.risingtidestudios.com/getPDF/?c=NKCQKDNU&PromotionalCode=spiced">OR Together with The Twenty Venture-backed Biotech Firms Most Likely to Succeed for only $395!</a></strong></p>
</div></td>
<td width="200" class="yello">
<h2>Limited Time Offer</h2>
<h1>Buy together for only $395!</h1>
<p>You'll receive<br>
<em>The Twenty Biotech <br>
Venture-backed Firms<br>
Most Likely to Succeed</em></p>
<p><strong>-
AND -</strong></p>
<p><em>Q3 '03 Biotech Investments, Mergers and Acquisitions</em><br>
for only $395</p><p><a href="https://secure.risingtidestudios.com/getPDF/?c=NKCQKDNU&PromotionalCode=spiced"><strong>Order Now! </strong></a></p></td>
</tr>
</table>
<P>This email is being sent to emboss@embnet.org. </P>
<P>If you would rather not receive these infrequent updates simply <A href="http://venturereporter.net/myaccount/k.asp?E=emboss@embnet.org">click here</A> and you will be removed instantly.<BR>
Alternatively, you may cut and paste the link below into your browser:<BR>
<A href="http://venturereporter.net/myaccount/k.asp?E=emboss@embnet.org">http://venturereporter.net/myaccount/k.asp?E=emboss@embnet.org</A> </P>
<P>Any questions or problems please forward this email to <A href="mailto:corrections@venturereporter.net">corrections@venturereporter.net</A>.<BR>
<br>
<EM><STRONG>Venture Reporter</STRONG></EM><BR>
307 West 36th Street, 10th Floor<BR>
New York, New York 10018<BR>
Phone: 646.473.2222</P>
</body>
</html>